AliveDx Suisse S.A. is pleased to announce the signing of a strategic distribution agreement with Ilex Medical. Under this agreement, Ilex Medical is authorized to distribute AliveDx’s MosaiQ® and LumiQ® solutions in Israel.
This partnership represents another important milestone in AliveDx’s strategy to expand its footprint in key markets and to support healthcare providers with innovative, high-value diagnostic technologies. Through this collaboration, AliveDx and Ilex Medical aim to enhance access to advanced diagnostics, helping clinicians shorten time to diagnosis and improve patient outcomes.
Transforming Diagnostics with MosaiQ® & LumiQ®
The MosaiQ® and LumiQ® platforms are designed to streamline laboratory workflows and increase operational efficiency through fully automated, multiplex microarray assay technology. These solutions enable laboratories to deliver faster, more cost-effective, and high-quality diagnostic results, benefiting both healthcare professionals and patients.
“We are pleased to partner with Ilex Medical, a trusted and dynamic organization whom I have known for many years active in the healthcare sector. This agreement reinforces AliveDx’s commitment to working with strong local partners to bring cutting-edge diagnostic solutions closer to clinicians and patients,” said Manuel O. Méndez, CEO of AliveDx.
“Expanding our partnerships with capable and forward-looking organizations like Ilex Medical is central to our Market strategy. We look forward to working closely together to drive adoption of advanced autoimmune and allergy diagnostics and to create meaningful clinical and economic value for healthcare providers,” said Kate Torno, Head of Commercial Europe, AliveDx.
About ILEX Medical
Ilex Medical is the owner of the “Ilex Group”, which brings together six leading companies in the field of medical devices operating in Israel and around the world. Ilex specializes in establishing automation projects in the world of diagnostics and providing innovative technological solutions to HMOs, hospitals, laboratories, research institutes, and blood banks in Israel and around the world.
“We are proud to partner with AliveDx and to add the MosaiQ® and LumiQ® platforms to our diagnostic portfolio. These innovative solutions align well with our commitment to providing advanced, reliable technologies that support better clinical decision-making and improved patient outcomes,” said Mr. Ziv Dahari, Deputy CEO, at Ilex.
Visit our websites to learn more:
